The phase III DREAMSEQ trial included 265 patients with treatment-naive BRAF V600-mutated metastatic melanoma, stratified by Eastern Cooperative Oncology Group PS 0 or 1 and lactate dehydrogenase (LDH) level; patients with untreated melanoma BMs (MBMs) were excluded. The gene discussed is BRAF; the disease is metastatic melanoma.